Skip to main content

Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program

Basic Details
Date
Tuesday, December 8, 2015
Type
Publication
Medical Product
angiotensin-converting enzyme (ACE) inhibitor
anticonvulsant
dabigatran
lisinopril
methotrexate
mycophenolate mofetil
paroxetine
ribavirin
selective serotonin reuptake inhibitor (SSRI)
simvastatin
sodium valproate
statin
valproic acid
warfarin
Description

This article describes the capability of the Mini-Sentinel pilot to provide prevalence rates of medication use among pregnant women delivering a liveborn infant.

The cohorts of interest are women ages 10 to 54 delivering a liveborn infant, and age- and date-matched non-pregnant women.

Materials

Maternal and Child Health Journal, December 8, 2015, DOI:10.1007/s10995-015-1878-8 

Information
Time Period
2001-2012
Data Source(s)
Mini-Sentinel Distributed Database (MSDD)
Related Assessment(s)
Drug Use Among Pregnant Women with Live Births
Author(s)

Susan Andrade ScD, Darren Toh ScD, Monika Houstoun PharmD, MPH, Katrina Mott MHS, Marilyn Pitts PharmD, Caren Kieswetter MD, MPH, Carrie Ceresa PharmD, MPH, Katie Haffenreffer BS, Marsha Reichman PhD

Corresponding Author

S. Andrade, Meyers Primary Care Institute (Fallon Community Health Plan, Reliant Medical Group, and University of Massachusetts Medical School), 630 Plantation St., Worcester, MA, 01605, USA. Email: sandrade@meyersprimary.org